WE BUILT THE GUIDE
WE WANTED.
THE STORY.
Pepgains started in 2024 as a frustration response. Every search for a peptide led to the same two places: an NEJM paper locked behind a paywall, or a Reddit thread where half the replies were “bro, just try it.”
Neither worked for someone trying to actually understand the science. So we sat down, pulled citations on the top 40 compounds, and wrote profiles the way we wish they'd been written: clear mechanism, honest evidence grading, real dosing data, proper risk disclosure.
Two years later the catalog has grown to 55+ compounds, the tools actually calculate your draw volume, and the newsletter reaches 8,400 researchers. Everything free. Everything cited. Still plain-spoken.
WHAT WE STAND FOR.
RESEARCH-FIRST.
Every claim is anchored to a real study or we don't publish it. Citations link out to PubMed, NEJM, or the original source so you can verify.
NO HIDDEN AGENDA.
We name our one affiliate (PEAK LAB). We don't run programmatic ads. We don't sell peptides. Our incentives are to be useful, not to maximize clicks.
RESPECT THE READER.
No 2,000-word SEO fluff. No scare copy. No fake urgency. If a piece can be said in 800 words, it's 800 words.
UPDATE THE RECORD.
Peptide research moves fast. When new Phase 3 data drops or a compound gets reclassified, we update the page and note the date. Living documents, not once-and-done.
WHAT WE COVER.
- → 55+ peptide profiles with mechanism, research, dosing
- → 4 interactive calculators (dosing, recon, half-life, stacks)
- → Weekly long-form research digests
- → Sourcing guides and COA literacy
- → Stack protocols with citations
WHAT WE DON'T DO.
- → Sell peptides or pharmacy services
- → Provide medical advice — we're educational only
- → Run programmatic ads — no ad trackers
- → Sell your data — ever
- → Fake urgency — scarcity isn't our pitch
WANT THE NEW STUFF FIRST?
Join 8,400 researchers getting the weekly Pepgains Dispatch — one compound, one paper, one number, every Tuesday.